[ad_1]
The American company Moderna announced that the full results of the latest clinical study confirmed a 94.1% efficacy of its COVID-19 vaccine and will require emergency clearance from both the Food and Drug Administration (FDA) in The United States, as well as the European Medicines Agency (EMA), inform Agepres.
Two weeks ago, the COVID-19 vaccine from the American company Moderna was declared 95% effective, according to preliminary data. No severe form of the disease occurred in the vaccinated group of participants.
Moderna representatives announced that they have already started the processes aimed at analyzing its vaccine by the EMA, but also the steps with the regulatory authorities on the drug market in Canada, Switzerland, Great Britain, Israel and Singapore, at in order to speed up authorization procedures.
At the same time, Moderna published the results of its Phase 3 COVE clinical study, conducted in 30,000 participants, which shows that the vaccine it developed is 94.1% efficient in preventing COVID-19 infection.
Through its approach on Monday, Moderna will become the first pharmaceutical company in the world to officially submit an application for authorization for a COVID-19 vaccine in the EU.
Last week, European Commission President Ursula von der Leyen announced that the EU had signed a contract with Moderna to purchase up to 160 million doses of the vaccine.
The contract includes an initial delivery of 80 million doses and an option for an additional 80 million doses to be delivered at a later date.
Moderna representatives believe this vaccine could be delivered to the EU in December at the earliest, if approved by the European Medicines Agency.
Publisher: ML
.
[ad_2]
Source link
